David Jones

7PUBLICATIONS
64CO-AUTHORS
NeurogeneticsEpidemiological methodsCancer therapy (excl. chemotherapy and radiation therapy)ChemotherapyPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Sep 23, 2026
A Genetic Risk Variant Associated With the Risk of Primary Biliary Cholangitis Is Inherited From Neanderthals.

|Apr 17, 2026
Network meta-analysis: relative clinical efficacy and safety of elafibranor versus seladelpar as second-line treatment for patients with primary biliary cholangitis.

|Mar 11, 2026
Optimising Primary thErapy in pRimAry biliary cholangitis (OPERA): protocol for a randomised, double-blind, placebo-controlled trial of enhanced primary therapy with obeticholic acid.

Sarah Dunn, Lysbeth Evans, Ciara Kennedy

|Mar 20, 2024
Primary biliary cholangitis drug evaluation and regulatory approval: Where do we go from here?

David E J Jones, Ulrich Beuers, Alan Bonder

|Apr 07, 2023
Regulation of immune responses in primary biliary cholangitis: a transcriptomic analysis of peripheral immune cells.

Victoria Mulcahy, Evaggelia Liaskou, Jose-Ezequiel Martin

|Feb 22, 2023
Impact of setanaxib on quality of life outcomes in primary biliary cholangitis in a phase 2 randomized controlled trial.

David Jones, Marco Carbone, Pietro Invernizzi

Pageof 2

Frequent Collaborators

3 joint publications

Douglas Thorburn

2 joint publications

Palak Trivedi

2 joint publications

Marco Carbone

2 joint publications

Emma Culver